Xconomy
SEPTEMBER 11, 2019
GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venture capital firm Avalon Ventures. Avalon said Tuesday that GSK (NYSE: GSK ) has agreed to buy the company, Sitari Pharmaceuticals, which has been developing a treatment for celiac disease.
Xconomy
AUGUST 17, 2016
San Diego’s Avelas Biosciences , founded in 2009 to advance a fluorescing biologic agent intended to help surgeons differentiate cancerous tissue from healthy tissue, has completed a $20 million Series C round of venture funding. and San Diego’s Avalon Ventures. The company also is planning to relocate to new offices, Stengone said.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
JULY 10, 2016
Bock, who died last Wednesday at 56, was a life sciences entrepreneur and investor who helped start or finance dozens of companies that have a combined market value estimated today at roughly $70 billion. When Xconomy came to San Diego in 2008, he also readily volunteered to help our editorial mission as an Xconomist. ).
Xconomy
SEPTEMBER 13, 2019
If a medical meeting in Barcelona this week was any indication, more help could be on the way. For decades, advanced lung cancer was a quick death sentence. That’s no longer a given, thanks in part to the arrival of immunotherapy.
Xconomy
AUGUST 30, 2017
Investment in experimental drugs for hearing loss, long an untapped field in the pharmaceutical industry, may be picking up, but drugs that actually help with these disorders remain elusive.
Xconomy
JANUARY 26, 2017
As has been the case for biotechs over the past year , insiders helped Anaptys get to the public market. The San Diego-based company sold 5 million shares at $15 apiece—in line with the $14 to $16 per share range it set earlier this month—and is now trading on the Nasdaq under the symbol “ANAB.”
Expert insights. Personalized for you.
56 
Let's personalize your content